Researchers from School of Pharmacy Report Findings in Diarylheptanoids (Design and Development of Novel Mitochondrial Targeted Nanocarriers, DQAsomes for Curcumin Inhalation)
By a News Reporter-Staff News Editor at Biotech Week -- A new study on Diarylheptanoids is now available. According to news reporting originating from London, United Kingdom, by NewsRx correspondents, research stated, "Curcumin has potent antioxidant and anti-inflammatory properties but poor absorption following oral administration owing to its low aqueous solubility. Development of novel formulations to improve its in vivo efficacy is therefore challenging."
Our news editors obtained a quote from the research from the School of Pharmacy, "In this study, formulation of curcumin-loaded DQAsomes (vesicles formed from the amphiphile, dequalinium) for pulmonary delivery is presented for the first time. The vesicles demonstrated mean hydrodynamic diameters between 170 and 200 nrn, with a xi potential of approximately +50 mV, high drug loading (up to 61%) and encapsulation efficiency (90%), resulting in enhanced curcumin aqueous solubility. Curcumin encapsulation in DQAsomes in the amorphous state was confirmed by X-ray diffraction and differential scanning calorimetry analysis. The existence of hydrogen bonds and cation-pi interaction between curcumin and vesicle building blocks, namely dequalinium molecules, were shown in lyophilized DQAsomes using FT-IR analysis. Encapsulation of curcumin in DQAsomes enhanced the antioxidant activity of curcumin compared to free curcumin. DQAsome dispersion was successfully nebulized with the majority of the delivered dose deposited in the second stage of the twin-stage impinger. The vesicles showed potential for rnitochondrial targeting."
According to the news editors, the research concluded: "Curcumin-loaded DQAsomes thus represent a promising inhalation formulation with improved stability characteristics and mitochondrial targeting ability, indicating a novel approach for efficient curcumin delivery for effective treatment of acute lung injury and the rationale for future in vivo studies."
For more information on this research see: Design and Development of Novel Mitochondrial Targeted Nanocarriers, DQAsomes for Curcumin Inhalation. Molecular Pharmaceutics, 2014;11(7):2334-2345. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
The news editors report that additional information may be obtained by contacting S. Zupancic, UCL Sch Pharm, Dept. of Pharmaceut, London WC1N 1AX, United Kingdom. Additional authors for this research include P. Kocbek, M.G. Zariwala, D. Renshaw, M.O. Gul, Z. Elsaid, K.M.G. Taylor and S. Somavarapu (see also Diarylheptanoids).
Keywords for this news article include: London, Europe, Alkanes, Curcumin, Catechols, Hydrocarbons, Nanocarriers, United Kingdom, Nanotechnology, Diarylheptanoids, Organic Chemicals, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC